MYC and renal cell carcinoma: Patients with non-S/R RCC and MYC v1 scores similar to those of S/R RCC (above the median of the S/R RCC group for MYC v1) had significantly worse outcomes in both the TCGA and CheckMate PD-1 cohorts (Fig. 2c; Supplementary Fig. S4; Supplementary Data 6).